DexCom, Inc. (DXCM) — 分析摘要
DexCom, Inc.（DXCM）的市值为29.46十亿美元，最近一年的营收同比增长了+15.6%。净利润率为17.9%。当前市盈率为31.7倍。
核心要点
- 营收同比变化+15.6%
- 净利润率17.9%
- 市盈率31.7倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，DXCM的营收增长为+15.6%，市盈率为31.7倍。
DexCom, Inc. (DXCM)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
11,100
总部
SAN DIEGO, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。